approaches to disease modification in MS
Last reviewed 01/2018
The following therapeutic strategies are accepted or are under investigation:
- non-specific immune suppression
- inhibition of interaction between T cell and antigen presenting cell
- interuption of lymphocyte migration into the central nervous system
- alteration of the balance of immune activation away from pro-inflammatory Th1 lymphocytes
- promotion of remyelination
In practise only beta-interferon has been shown to alter the activity of the disease and possibly to reduce disability. Intravenous immunoglobulin and glatitramer acetate are promising alternatives.
non-specific immune suppression
inhibition of T cell - antigen presenting cell interaction
interruption of lymphocyte migration